Pioneers in pulsed field ablation

Over 15 years of robust preclinical research in IRE and clinical application of pulsed field cardiac ablation yielded the PulseSelect™ PFA system for paroxysmal and persistent AF. The Medtronic PFA suite launches a new era in safety and an exciting shift in precision and efficiency in PFA electrophysiology for atrial fibrillation treatment with the Affera™ mapping and ablation system, integrated with the only all-in-one dual-energy Sphere-9™ PFA catheter.




Versatile PFA tools to tailor lesion sets

Wide area focal

Wide area focal PFA catheters provide the ability to tailor lesion sets across the anatomy, ensuring consistent and reliable isolation.2

An all-in-one PFA solution to map, ablate, and validate, the Sphere-9™ catheter is the only wide area focal dual-energy pulsed field/radiofrequency catheter, exclusively integrated with the Affera™ mapping and ablation system.



This is an image of the Affera™ mapping system demonstrating the wide area focal dual energy PF/RF catheter making tailored lesion sets.


SPHERE Per-AF — superior efficiency compared to traditional RF3

RCT IDE comparing Affera™ mapping and ablation system with Sphere-9™ catheter to CARTO®* navigation and mapping system with THERMOCOOL SMARTTOUCH®* SF (STSF) catheter

420 patients | drug-refractory persistent AF | 23 centers | 40+ operators

  • 1.4% primary safety events versus 1% when using STSF
  • 74% primary effectiveness rate
  • 80% effectiveness in more than 10 cases4
  • 25+ minutes saved per procedure

Single shot

Single-shot PFA catheters allow you to achieve wide area circumferential lesions designed with pulmonary vein isolation (PVI) in mind.

The PulseSelect™ PFA system features a single-shot over-the-wire PFA catheter, enabling mapping and precise lesion delivery with the freedom to adapt to your preferred workflow.

This is an image of the PulseSelect™ pulsed field ablation (PFA) system being used in the body.

PULSED AF — the safest PFA IDE trial published to date.5

IDE evaluating the safety and effectiveness of the PulseSelect™ PFA system.

300 patients | drug-refractory PAF and PsAF patients | 41 centers | 67 operators


Primary safety events

0.7%


Efficacy

Freedom from AF/AT/AFL

This is a bar chart showing the efficacy data from the PULSED AF clinical trial.


Medtronic PFA history


Related products